Bristol Myers Squibb Company $BMY Stock: Kestra Advisory Services LLC Raises Position

Kestra Advisory Services LLC increased its position in Bristol Myers Squibb Company (NYSE:BMY) by 13.5% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 260,476 shares of the biopharmaceutical company’s stock after purchasing an additional 30,977 shares during the period. Kestra Advisory Services LLC’s holdings in Bristol Myers Squibb were worth $16,254,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Davis Asset Management L.P. acquired a new stake in Bristol Myers Squibb during the 2nd quarter valued at $27,000. Addison Advisors LLC acquired a new stake in shares of Bristol Myers Squibb in the second quarter worth $32,000. Groupe la Francaise boosted its position in shares of Bristol Myers Squibb by 562.9% in the second quarter. Groupe la Francaise now owns 590 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 501 shares during the period. Arlington Trust Co LLC purchased a new position in shares of Bristol Myers Squibb during the second quarter valued at $35,000. Finally, Kilter Group LLC purchased a new position in shares of Bristol Myers Squibb during the second quarter valued at $35,000. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on BMY shares. HSBC reissued a “hold” rating and set a $65.00 price target (up from $60.00) on shares of Bristol Myers Squibb in a research report on Thursday, September 10th. Morgan Stanley decreased their price objective on Bristol Myers Squibb from $41.00 to $40.00 and set an “underweight” rating for the company in a research report on Friday, October 30th. Piper Sandler lowered their target price on Bristol Myers Squibb from $82.00 to $78.00 and set an “overweight” rating on the stock in a research note on Monday, October 26th. Cantor Fitzgerald dropped their target price on Bristol Myers Squibb from $59.00 to $53.00 and set a “neutral” rating on the stock in a report on Thursday, October 8th. Finally, Raymond James Financial assumed coverage on shares of Bristol Myers Squibb in a research report on Wednesday, August 5th. They issued a “strong-buy” rating for the company. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, sixteen have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $65.46.

Insider Activity at Bristol Myers Squibb

In other Bristol Myers Squibb news, Director Julia A. Haller sold 3,800 shares of the business’s stock in a transaction that occurred on Thursday, November 5th. The shares were sold at an average price of $63.31, for a total value of $240,578.00. Following the completion of the sale, the director directly owned 30,279 shares of the company’s stock, valued at $1,916,963.49. The trade was a 11.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Phil M. Holzer sold 500 shares of the business’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the sale, the senior vice president directly owned 16,862 shares of the company’s stock, valued at $1,138,185. This represents a 2.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.05% of the stock is currently owned by company insiders.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb reported 56-week Phase 3 results for Camzyos (mavacamten) in children with symptomatic obstructive hypertrophic cardiomyopathy. Sustained efficacy could support the drug’s potential in a broader patient population, though the report does not say that pediatric use has been approved. Article: Bristol-Myers Squibb Says Camzyos Shows Sustained Efficacy in Phase 3 Pediatric Trial
• Positive Sentiment: A multi-year AI alliance expands the company’s neuroscience efforts, potentially supporting future drug discovery, although the supplied report gives no financial terms or near-term revenue outlook. Article: Bristol Myers Squibb Expands Neuroscience Push With Multi Year AI Alliance
• Positive Sentiment: Recent coverage also highlighted FDA accelerated approval for ZENBEXUS in multiple myeloma and positive trial updates in other diseases. These developments add to the pipeline narrative, though investors may weigh how much expected optimism is already reflected in the shares. Article: Bristol Myers Squibb Wins FDA Approval
• Neutral Sentiment: A company director disclosed selling 3,800 shares. Insider sales can attract attention, but the filing alone does not establish the director’s reason or signal a change in the company’s outlook. SEC Form 4 filing
• Negative Sentiment: A dividend-focused article flags potential pressure from an expected $1.5 billion–$2 billion decline in blood-thinner sales and the company’s debt burden. That raises questions about dividend sustainability, though the article does not establish that a cut is imminent. Article: Bristol Myers Squibb Yields Over 4%. Can Its Dividend Survive 2027?

Bristol Myers Squibb Stock Performance

Shares of BMY stock opened at $62.20 on Monday. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.59 and a quick ratio of 1.44. Bristol Myers Squibb Company has a fifty-two week low of $45.26 and a fifty-two week high of $68.64. The stock’s 50-day moving average is $62.34 and its two-hundred day moving average is $60.11. The firm has a market cap of $127.15 billion, a P/E ratio of 13.79, a PEG ratio of 0.32 and a beta of 0.20.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share for the quarter, topping analysts’ consensus estimates of $1.10 by $0.25. The company had revenue of $13.07 billion during the quarter, compared to the consensus estimate of $12.72 billion. Bristol Myers Squibb had a return on equity of 60.48% and a net margin of 18.47%. The business’s quarterly revenue was up 6.9% on a year-over-year basis. During the same period last year, the business earned $1.63 EPS. Analysts predict that Bristol Myers Squibb Company will post 6.45 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, November 2nd. Investors of record on Friday, October 2nd were issued a $0.63 dividend. The ex-dividend date was Friday, October 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.1%. Bristol Myers Squibb’s dividend payout ratio is currently 55.88%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease.

The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.

Bristol Myers Squibb was formed in 1989 through the merger of Bristol-Myers, founded in 1887, and the E.